TY - JOUR
T1 - Dynamic IMRT treatments of sinus region tumors
T2 - Comparison of Monte Carlo calculations with treatment planning system calculations and ion chamber measurements
AU - Court, Laurence E.
AU - Jahnke, Lennart
AU - Chin, David
AU - Song, Jun
AU - Cormack, Robert
AU - Zygmanski, Piotr
AU - Tishler, Roy B.
AU - Chin, Lee
PY - 2006/10
Y1 - 2006/10
N2 - Results are presented comparing Monte Carlo (MC) calculations for dynamic IMRT treatments of tumors in the sinus region with Eclipse treatment planning system dose calculations, and ion chamber measurements. The EGS4nrc MC code, BEAMnrc, was commissioned to simulate a Varian 21Ex Linac for both open and IMRT fields. The accuracy of the simulation for IMRT plans was evaluated using a head phantom by comparing MC, Eclipse, TLD results, and ion chamber in solid water phantom measurements. The MC code was then used to simulate dose distributions for five patients who were treated using dynamic IMRT for tumors in the sinus region. The results were compared with absolute and relative dose distributions calculated using Eclipse (pencil beam, modified-Batho inhomogeneity correction). Absolute dose differences were also compared with ion chamber results. Comparison of the doses calculated on the head phantom using MC, compared with Eclipse, ion chamber, and TLD measurements showed differences of -3.9%, -1.4%, and -2.0%, respectively (MC is colder). Relative dose distributions for the patient plans calculated using MC agreed well with those calculated using Eclipse with respect to targets and critical organs, indicating the modified-Batho correction is adequate. Average agreement for mean absolute target doses between MC and Eclipse was -3.0 ± 2.3% (1 s.d.). Agreement between ion chamber and Eclipse for these patients was -2.2 ± 1.9%, compared with 0.2 ± 2.0% for all head and neck IMRT patients. When Eclipse doses were corrected based on ion chamber results, agreement between MC and Eclipse was -0.7 ± 2.0%, indicating a small systematic uncertainty in the doses calculated using the treatment planning system for this subset of patients.
AB - Results are presented comparing Monte Carlo (MC) calculations for dynamic IMRT treatments of tumors in the sinus region with Eclipse treatment planning system dose calculations, and ion chamber measurements. The EGS4nrc MC code, BEAMnrc, was commissioned to simulate a Varian 21Ex Linac for both open and IMRT fields. The accuracy of the simulation for IMRT plans was evaluated using a head phantom by comparing MC, Eclipse, TLD results, and ion chamber in solid water phantom measurements. The MC code was then used to simulate dose distributions for five patients who were treated using dynamic IMRT for tumors in the sinus region. The results were compared with absolute and relative dose distributions calculated using Eclipse (pencil beam, modified-Batho inhomogeneity correction). Absolute dose differences were also compared with ion chamber results. Comparison of the doses calculated on the head phantom using MC, compared with Eclipse, ion chamber, and TLD measurements showed differences of -3.9%, -1.4%, and -2.0%, respectively (MC is colder). Relative dose distributions for the patient plans calculated using MC agreed well with those calculated using Eclipse with respect to targets and critical organs, indicating the modified-Batho correction is adequate. Average agreement for mean absolute target doses between MC and Eclipse was -3.0 ± 2.3% (1 s.d.). Agreement between ion chamber and Eclipse for these patients was -2.2 ± 1.9%, compared with 0.2 ± 2.0% for all head and neck IMRT patients. When Eclipse doses were corrected based on ion chamber results, agreement between MC and Eclipse was -0.7 ± 2.0%, indicating a small systematic uncertainty in the doses calculated using the treatment planning system for this subset of patients.
KW - Dose calculations
KW - Heterogeneity correction
KW - IMRT
KW - Sinus
UR - http://www.scopus.com/inward/record.url?scp=33750202368&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33750202368&partnerID=8YFLogxK
U2 - 10.1177/153303460600500505
DO - 10.1177/153303460600500505
M3 - Article
C2 - 16981791
AN - SCOPUS:33750202368
SN - 1533-0346
VL - 5
SP - 489
EP - 495
JO - Technology in Cancer Research and Treatment
JF - Technology in Cancer Research and Treatment
IS - 5
ER -